Branches
Curie Oncology (Novena)
Mon—Fri: 8:30 AM — 5:30 PM
Sat: 8:30 AM — 12:30 PM
Closed on Sunday and Public Holidays
Photos
Curie Oncology (Farrer)
Mon—Fri: 8:30 AM — 5:30 PM
Sat: 8:30 AM — 12:30 PM
Closed on Sunday and Public Holidays
Photos
Experts
Ongoing trials at Curie Oncology
6 trials shown
A Novel Limb Cryocompression System for Prevention of Chemotherapy Induced Peripheral Neuropathy - Expansion Study
The study conducted on cancer patients is designed to test safety and efficacy of limb hypothermia in cancer patients using the new Paxman Limb Cryocompression System (PLCS). Ultim
- Study number:
- NCT05606068
- Cohorts:
- 1
- Study phase:
- N/A
- Overall status:
- Not yet recruiting
- Study type:
- Chemotherapy, Supportive interventions
A Study of Dato-DXd Versus Investigator's Choice Chemotherapy in Patients With Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer, Who Are Not Candidates for PD-1/PD-L1 Inhibitor Therapy (TROPION-Breast02)
This is a Phase III, randomised, open-label, 2 arm, multicentre, international study assessing the efficacy and safety of Dato-DXd compared with ICC in participants with locally re
- Study number:
- NCT05374512
- Cohorts:
- 1
- Study phase:
- 3
- Overall status:
- Recruiting
- Study type:
- Immunotherapy, Chemotherapy
A Study of Nivolumab-relatlimab Fixed-dose Combination Versus Regorafenib or TAS-102 in Participants With Later-lines of Metastatic Colorectal Cancer
The purpose of this study is to evaluate relatlimab in combination with nivolumab, administered as a fixed-dose combination (nivolumab-relatlimab FDC, also referred to as BMS-98621
- Study number:
- NCT05328908
- Cohorts:
- 1
- Study phase:
- 3
- Overall status:
- Recruiting
- Study type:
- Immunotherapy, Targeted therapy, Chemotherapy
A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers
This study is being done to find out if zanidatamab, when given with chemotherapy plus or minus tislelizumab, is safe and works better than trastuzumab given with chemotherapy. Th
- Study number:
- NCT05152147
- Cohorts:
- 1
- Study phase:
- 3
- Overall status:
- Recruiting
- Study type:
- Immunotherapy, Targeted therapy, Chemotherapy, Biomarker
A Study of Lomvastomig (RO7121661) and Tobemstomig (RO7247669) Compared With Nivolumab in Participants With Advanced or Metastatic Squamous Cell Carcinoma of the Esophagus
This is a Phase II, randomized, blinded, active-controlled, global, multicenter study designed to evaluate the safety and efficacy of lomvastomig and tobemstomig, compared with niv
- Study number:
- NCT04785820
- Cohorts:
- 1
- Study phase:
- 2
- Overall status:
- Recruiting
- Study type:
- Immunotherapy
Study to Evaluate Monotherapy and Combination Immunotherapies in Participants With PD-L1 Positive Non-small Cell Lung Cancer
This randomized phase 2 open-label study will evaluate the safety and efficacy of zimberelimab (AB122) monotherapy, domvanalimab (AB154) in combination with zimberelimab, and domva
- Study number:
- NCT04262856
- Cohorts:
- 1
- Study phase:
- 2
- Overall status:
- Active, not recruiting
- Study type:
- Immunotherapy, Targeted therapy, Biomarker